[Experiences with monoclonal antibody orthoclone OKT3 following liver transplantation].
In 7 patients 10 cycles (5 to 21 days, dosage: 30 to 430 mg, median 138 mg) of OKT3 therapy were performed after liver transplantation. In all patients reactivation of an EBV-infection with hepatitis was observed. Two patients treated with high dosages (430 mg respectively 195 mg) developed lymphoproliferative lesions. In one patient with persistent EBV-infection (dosage: 360 mg) a B-cell-lymphoma was diagnosed. This patient died 26 months after transplantation.
Kraemer-Hansen
H
H
Chirurgische Universitätsklinik, Universität Hamburg.
Henne-Bruns
D
D
Schröder
S
S
Löning
T
T
Dittmer
R
R
Kremer
B
B
D005260:Female; D006084:Graft Rejection; D006525:Hepatitis, Viral, Human / Q000382:microbiology*; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D016031:Liver Transplantation; D016393:Lymphoma, B-Cell / Q000209:etiology; D008232:Lymphoproliferative Disorders / Q000209:etiology; D008297:Male; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000276:immunology; D012008:Recurrence
D016853:Muromonab-CD3
Erfahrungen mit dem monoklonalen Antikörper Orthoclone OKT3 nach Lebertransplantation.